The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.
Belgium-based Bone Therapeutics’ Phase III osteoarthritis study using the company’s enhanced viscosupplement JTA-004 failed to meet primary and critical secondary endpoints.
Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
Grand River Aseptic Manufacturing (GRAM) inked a deal with Janssen Pharmaceutical to support the manufacturing of the Johnson & Johnson company’s Covid-19 vaccine candidate.
The U.S. Food and Drug Administration granted approval of Endo International’s Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is the first FDA-approved injectable treatment for cellulite.
U.S. drugmaker Pfizer Inc. signed a long-term agreement with glass maker Corning Inc. to procure vials for storing drugs.
A panel of the European medicines regulator recommended approving Novo Nordisk’s new diabetes pill Rybelsus, further boosting prospects for the Danish drugmaker with the company’s first-of-a-kind, non-injectable treatment.
Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.